Abbott Laboratories reports $11.16 billion revenue for quarter ended March 31, 2026, up 7.8%
Abbott Laboratories reported revenue of $11.16 billion for the quarter ended March 31, 2026, an increase of 7.8% from the same quarter a year earlier ($10.36 billion).
For the same period it posted net income of $1.08 billion, down 18.7%, or $0.61 per diluted share (0.76 a year earlier).
That is a net margin of 9.6%.
On Sanad's AAOIFI Standard 21 screen, Abbott Laboratories is currently compliant: interest-bearing debt is 17.2% of market capitalisation (limit 30%), and impure income is 0.7% of revenue (limit 5%).
Is Abbott Laboratories halal?
See the full AAOIFI screening of Abbott Laboratories
See the full AAOIFI screening of Abbott Laboratories
Source: 10-Q filed with the U.S. Securities and Exchange Commission on April 29, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.